What are the requirements for medical insurance reimbursement of enzalutamide/enzalutamide?

Enzalutamide/Enzalutamide (Enzalutamide), as a new generation of androgen receptor inhibitors, has been widely used clinically for the treatment of advanced prostate cancer. With the continuous improvement of the domestic cancer treatment system, enzalutamide has been included in the national medical insurance directory. This policy adjustment has greatly reduced the financial burden of patients. However, there are usually certain conditions for the use of medical insurance, and not all patients can be reimbursed indiscriminately. Therefore, understanding the reimbursement requirements is particularly important for patients and their families.

Currently, the core requirements for enzalutamide medical insurance reimbursement are highly related to its indications, which are usually targeted at patients diagnosed with castration-resistant prostate cancer (CRPC), especially in the progressive stage of the disease after failure of endocrine therapy. When applying for medical insurance reimbursement, patients need to provide relevant medical diagnosis certificates and standardized medical records, including pathology reports, imaging examination results, and medication orders, etc., to ensure that they meet the medical insurance review standards. In addition, the implementation details of medical insurance policies in different regions may be slightly different. For example, some provinces and cities have certain restrictions on patient age, previous medication use, or whether it is accompanied by bone metastasis. Therefore, in actual operations, you should consult with the local medical insurance department or the attending doctor for confirmation.

It is worth noting that after enzalutamide entered the medical insurance catalog, the payment ratio of the drug dropped significantly. Usually, patients only need to bear a smaller proportion of the cost to obtain the full course of treatment drugs. This is an important favorable policy for patients who take long-term oral drugs. From a patient's perspective, medical insurance reimbursement not only relieves financial pressure, but also improves treatment compliance, helping more patients adhere to standardized treatment and extend survival benefits.

In general, the requirements for medical insurance reimbursement of enzalutamide are mainly reflected in the limitation of indications, standardized submission of medical documents, and policy differences based on local conditions.

Reference materials:https://www.xtandi.com/